AstraZeneca plc (AZN) Ordinary US$0.25
124.00p
(0.89%)
- Add to watchlist
- Create an alert
- This stock can be held in a
124.00p
(0.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
124.00p
(0.89%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
FDA rejects self-injectable version of AstraZeneca lupus drug
3 February 2026 07:34
(Sharecast News) - The US health regulator has rejected an application by AstraZeneca to launch a self-injectable version of its lupus treatment Saphnelo, the drugs giant confirmed on Tuesday.
-
Astrazeneca's Imfinzi receives EU recommendation from CHMP
2 February 2026 07:29
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its gastric and gastroesophageal junction cancer treatment, Imfinzi, has been recommended for approval in the European Union by the Committee for...
-
AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals
30 January 2026 07:03
(Sharecast News) - Drugmaker Astrazeneca said on Friday that it has expanded its weight‑management pipeline after striking a strategic collaboration with CSPC Pharmaceuticals to develop a series of...
-
AstraZeneca unveils $15bn China investment
29 January 2026 07:37
(Sharecast News) - AstraZeneca is to invest $15bn in China by the end of the decade, the UK drugs giant confirmed on Thursday, as part of the prime minister's visit to the country.
-
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27 January 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
-
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles
22 December 2025 08:52
(Sharecast News) - AstraZeneca on Monday reported mixed regulatory and clinical news, with its breast cancer drug Enhertu securing a US breakthrough therapy designation in early disease, while a late-stage...
-
AstraZeneca chalks up dual regulatory wins in cancer and immunology
16 December 2025 07:42
(Sharecast News) - Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.
-
AstraZeneca secures US approval for Imfinzi in gastric cancer
26 November 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT chemotherapy in the treatment of adult patients with resectable,...
-
AstraZeneca to spend $2bn in US manufacturing push
24 November 2025 07:01
(Sharecast News) - AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on Monday.
-
AstraZeneca receives FDA approval for expanded Koselugo usage
20 November 2025 07:12
(Sharecast News) - The US Food and Drug Administration has approved the expanded usage of AstraZeneca's Koselugo drug to adults with neurofibromatosis type 1 (NF1) - a rare, progressive, genetic...
-
Director dealings: 3i execs buy the dip, AstraZeneca CFO offloads shares
14 November 2025 13:53
(Sharecast News) - London-listed companies 3i Group and AstraZeneca disclosed fresh director dealings on Wednesday, with senior executives at the private equity group adding to their holdings while...
-
AstraZeneca beats Q3 expectations, maintains FY outlook
6 November 2025 09:18
(Sharecast News) - Drugmaker AstraZeneca reiterated its full-year guidance on Thursday as it posted a third-quarter earnings beat, driven by solid sales of its cancer, heart and kidney disease drugs.
Company announcements Announcements
-
Update on Saphnelo subcutaneous administration
3 February 2026 07:00
AstraZeneca
-
Total Voting Rights
2 February 2026 15:00
AstraZeneca
-
Imfinzi recommended in EU for early gastric cancer
2 February 2026 07:05
AstraZeneca
-
AstraZeneca begins trading on NYSE
2 February 2026 07:00
AstraZeneca
-
AstraZeneca agrees obesity and T2D deal with CSPC
30 January 2026 07:00
AstraZeneca
-
AstraZeneca invests $15bn in China through 2030
29 January 2026 09:51
AstraZeneca
-
AstraZeneca to complete direct listing on NYSE
20 January 2026 07:00
AstraZeneca
-
AZN new Head of Investor Relations Joris Silon
8 January 2026 07:00
AstraZeneca
-
Total Voting Rights
2 January 2026 15:00
AstraZeneca
-
Director/PDMR Shareholding
22 December 2025 11:00
AstraZeneca
-
Enhertu granted BTD for post-neoadjuvant early BC
22 December 2025 07:30
AstraZeneca
-
Update on LATIFY Phase III trial of ceralasertib
22 December 2025 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2026. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.